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REVIEW
Abstract: Paclitaxel is an anticancer agent effective for the treatment of breast, ovarian,
lung, and head and neck cancer. Because of water insolubility, paclitaxel is formulated with
the micelle-forming vehicle Cremophor EL to enhance drug solubility. However, the addition
of Cremophor EL results in hypersensitivity reactions, neurotoxicity, and altered
pharmacokinetics of paclitaxel. To circumvent these unfavorable effects resulting from the
addition of Cremophor EL, efforts have been made to develop new delivery systems for
paclitaxel administration. For example, ABI-007 is a Cremophor-free, albumin-stabilized,
nanoparticle paclitaxel formulation that was found to have significantly less toxicity than
Cremophor-containing paclitaxel in mice. Pharmacokinetic studies indicate that in contrast to
Cremophor-containing paclitaxel, ABI-007 displays linear pharmacokinetics over the clinically
relevant dose range of 135–300 mg/m2. In a phase III study conducted in patients with metastatic
breast cancer, patients treated with ABI-007 achieved a significantly higher objective response
rate and time to progression than those treated with Cremophor-containing paclitaxel. Together
these findings suggest that nanoparticle albumin-bound paclitaxel may enable clinicians to
administer paclitaxel at higher doses with less toxicity than is seen with Cremophor-containing
paclitaxel. The role of this novel paclitaxel formulation in combination therapy with other
antineoplastic agents needs to be determined.
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Introduction
Paclitaxel is a hydrophobic antineoplastic agent demonstrating significant antitumor
activity against a broad spectrum of human malignancies, including breast, lung,
and ovarian cancer. Following the identification of paclitaxel as the active ingredient
in crude ethanolic extracts of the bark of the Pacific yew tree, Taxus brevifolia,
development of this drug was suspended for over a decade because of problems in
drug formulation, drug supply, and controversies regarding the mechanism of action
(Wani et al 1971). After investigation of a large variety of excipients to enable
parenteral administration of paclitaxel, the formulation approach using the
polyoxyethylated castor oil derivative Cremophor
® EL (CrEL) represented the most
viable option (Adams et al 1993). Currently, paclitaxel is commercially marketed in
a formulation that contains a solvent system of CrEL and dehydrated ethanol. CrEL
is widely used as a vehicle for the solubilization of a number of other hydrophobic
drugs including anesthetics, vitamins, sedatives, photosensitizers, immuno-
suppressants, and investigational anticancer drugs. The amount of CrEL in Taxol
®
per administration is relatively high, and therefore its toxicological and
pharmacological behavior in the context of chemotherapeutic treatment with paclitaxel
is of major importance (Gelderblom et al 2001; van Zuylen, Verweij, et al 2001).
The drawbacks presented by the presence of CrEL in the paclitaxel formulation
have been an incentive for extensive research to develop alternative delivery forms.
Currently, several strategies are in progress to develop a CrEL-free formulation of
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paclitaxel, including biological approaches (oral
administration), chemical approaches (prodrugs, analogs),
and pharmaceutical approaches (use of co-solvents,
emulsions, liposomes, cyclodextrins, microspheres,
nanoparticles) (Terwogt et al 1997; Nuijen et al 2001). The
most extensively studied alternative paclitaxel preparation
is ABI-007, a human albumin-stabilized, lyophilized
nanoparticle formulation, with an average size of 130 nm,
which is free of CrEL and ethanol (Desai et al 2002).
Comparative properties of this paclitaxel formulation and
the conventional CrEL-containing formulation are
highlighted in Table 1 and are discussed further.
Preclinical studies of paclitaxel
disposition
In preclinical studies performed in mice, ABI-007 was
shown to have significantly less toxicity than Taxol (Desai
et al 2002). In five different human tumor xenografts (NCI-
H522 lung, MX-1 breast, SKOV-3 ovarian, PC-3 prostate,
and HT29 colon), the maximum tolerated dose of ABI-007
was 1.5- to 2-fold greater than that of Taxol. In addition, at
the maximum tolerated dose, ABI-007 showed superior
efficacy to Taxol, especially in breast, colon, and ovarian
models.
Plasma pharmacokinetics and partitioning of
radiolabeled paclitaxel from ABI-007 and Taxol into red
blood cells and tumor tissue was examined in an MX-1
xenograft tumor model over 24 hours following a single
tail vein injection of paclitaxel 20 mg/kg (Desai et al 2003).
ABI-007 distributed more rapidly and extensively than
Taxol, as shown by a 5-fold larger volume of distribution,
lower maximum concentration, and lower area under the
plasma concentration-time curve (AUC), suggesting that
CrEL prevented the distribution of Taxol out of the
circulation and into the tissues. ABI-007 demonstrated a
significantly lower plasma/blood ratio of paclitaxel
(p < 0.0001). ABI-007 also distributed more effectively into
MX-1 tumor with a tumor AUC of paclitaxel 1.6-fold higher
with ABI-007 than with Taxol (p < 0.0001).
A series of preclinical studies and cell biology
experiments have been conducted to investigate the
mechanism of enhanced tumor penetration observed with
ABI-007. A current hypothesis is that ABI-007 reaches the
tumor by a novel mechanism (Desai et al 2004; Garber
2004). It has been suggested that some ABI-007 accesses
the tumor via leaky junctions in the tumor vasculature and
is retained by the tumor’s impaired lymphatic system.
Albumin has been shown to be transported across endothelial
cells by a specific receptor (gp60)-mediated caveolar
transport (John et al 2003). It was hypothesized that
nanoparticle albumin-bound paclitaxel might be transported
similarly, and increased ABI-007 transport by endothelial
gp60-mediated transcytosis was recently reported (Desai et
al 2004). This process has been shown to be selectively
inhibited by Taxol (Desai et al 2004). This finding may partly
explain the increased intratumoral concentrations of
paclitaxel seen following ABI-007 administration relative
to Taxol.
Paclitaxel pharmacokinetics
Various studies have shown that CrEL alters the
pharmacokinetic behavior of many drugs administered
intravenously, including cyclosporin, anthracyclines,
etoposide, the irinotecan metabolite SN38, the
photosensitizer C8KC, and paclitaxel. The most common
effect is a substantial increase in systemic exposure to the
studied agent with a concomitantly reduced systemic
clearance, as was first described for paclitaxel in a mouse
model. Various proposed causes of the CrEL–drug
interactions have been put forward, including altered
protein-binding characteristics (Sykes et al 1994), altered
hepatobiliary secretion (Ellis and Webster 1999), and
inhibition of endogenous P-glycoprotein-mediated biliary
secretion, thereby reducing elimination of drugs (Gianni et
al 1997). In the isolated perfused rat liver, CrEL inhibited
the hepatic elimination of paclitaxel, preventing the drug
from reaching the sites of metabolism and excretion (Ellis
and Webster 1999). However, studies indicate that drug-
transporting P-glycoproteins are not essential for normal
hepatobiliary secretion of paclitaxel (Sparreboom et al
Table 1 Comparative properties of nanoparticle albumin-
bound paclitaxel and Cremophor EL-containing paclitaxel
Nanoparticle Cremophor
albumin-bound EL-based
paclitaxel paclitaxel
(ABI-007)    (eg, Taxol)
Hypersensitivity
reactions No Yes
Leaches plasticizers
from intravenous tubing No Yes
Forms micelles in plasma No Yes
Transported via gp60
receptor on vascular
endothelial cells Yes No
Nonlinear pharmacokinetics No Yes
Drug–drug interactions Not known YesTherapeutics and Clinical Risk Management 2005:1(2) 109
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1997), suggesting that this protein does not play a major
role.
In view of the very small volume of distribution of CrEL,
it is likely that the pharmacokinetic interaction observed
with paclitaxel takes place within the central blood
compartment. This was confirmed by in vitro experiments
demonstrating that encapsulation of the model drug
paclitaxel within the hydrophobic interior of CrEL micelles
takes place in a concentration-dependent manner, causing
changes in cellular partitioning and blood/plasma
concentration ratios of paclitaxel (Sparreboom et al 1999;
Loos et al 2002). It was shown that the affinity of paclitaxel
was (in decreasing order) CrEL > plasma > human serum
albumin, with CrEL present above the critical micellar
concentration (ie, ~ 0.01%). Since the effect was also
observed in the absence of plasma proteins, it could not
have been caused by altered protein binding or by an
increased affinity of paclitaxel for protein dissociation
products that are produced by the action of CrEL on native
lipoproteins (Sykes et al 1994).
 These findings are consistent
with the hypothesis that paclitaxel can be entrapped within
CrEL micelles, and that these micelles act as the principal
carrier of paclitaxel in the systemic circulation.
An intriguing feature of Taxol
 pharmacokinetics is a
distinct dose-dependent pharmacokinetic behavior, with
clearance values decreasing substantially with an increase
in drug dose. This effect is particularly evident with 3-hour
infusion regimens, and CrEL has been linked to this
phenomenon. It has been shown that the percentage of total
paclitaxel trapped in micelles increases disproportionately
with higher doses of CrEL administered (van Zuylen et al
2000; van Zuylen, Karlsson, et al 2001), thereby influencing
the unbound drug concentration and making it less available
for distribution to tumor, tissues, metabolism, and biliary
and intestinal secretion. Indeed, the free fraction of paclitaxel
is inversely related to CrEL concentrations in vitro (Brouwer
et al 2000), and CrEL has also been shown to alter the
blood/plasma concentration ratios in vivo by reducing drug
uptake in red blood cells (van Zuylen, Karlsson, et al 2001).
Interestingly, when paclitaxel dissolved in another vehicle
was administered to mice, no pharmacokinetic nonlinearity
in plasma concentration profiles was evident (Sparreboom
et al 1996a, 1996b). The concentrations in tissues also
increased linearly with escalating doses even when dissolved
in CrEL, suggesting linear kinetics for the unbound drug.
The nonlinearity in paclitaxel pharmacokinetics was
previously described using empirical models using both
saturable elimination and distribution, where the saturable
distribution has been described as saturable transport
(Sonnichsen et al 1994) or saturable binding (Karlsson et al
1999). A recent study demonstrated that a mechanistic model
could be used to describe the nonlinear kinetics of the drug
using simultaneous description of total and unbound plasma
concentrations, whole blood concentrations, and
concomitant CrEL levels (Henningsson et al 2001). This
pharmacokinetic model has a foundation in the known
properties of paclitaxel as determined with micellar trapping
of paclitaxel, distribution to red blood cells, and binding to
serum albumin, α1-acid glycoprotein, and platelets. The
results of that study showed that the nonlinear
pharmacokinetics of paclitaxel are predominantly explained
by nonlinear binding to CrEL and that the unbound drug
displayed linear pharmacokinetics when administered over
a 3-hour period.
The drug fraction not bound to serum proteins or CrEL
is a rather small fraction of the total under normal
physiological conditions, and at high concentrations,
paclitaxel is mainly bound to CrEL. From simulated
concentration components in patients treated with 24-hour
infusions in which CrEL concentrations are rather low, it
was demonstrated that the linear paclitaxel binding to serum
proteins and binding to blood cells are of greater importance
than the CrEL binding (Henningsson et al 2001). The
schedule-dependent clearance of CrEL has a serious clinical
ramification, in that systemic exposure to unbound paclitaxel
is a function of infusion duration. This was confirmed in a
randomized, comparative clinical trial evaluating drug
disposition characteristics following 1- versus 3-hour
infusions (Gelderblom et al 2002). The AUC of unbound
paclitaxel after a 1-hour infusion was 24% (p = 0.009)
less than the AUC demonstrated by the 3-hour infusion
group, despite significantly higher peak concentrations
associated with the shorter infusion time (0.26 ± 0.007 vs
0.15 ± 0.07 µmol/L; p = 0.0002). Most importantly, this effect
translated into more severe hematological toxicity with the
3-hour schedule of drug administration (Gelderblom et al
2002), suggesting that the various infusion schedules
currently employed for paclitaxel dosing are neither
interchangeable nor pharmacologically equivalent.
Paclitaxel pharmacokinetics following ABI-007
administration have been studied in 16 patients who received
doses ranging from 135 to 375 mg/m
2 using non-
compartmental analysis (Ibrahim et al 2002; Hawkins et al
2004). Pharmacokinetic parameters are summarized in
Table 2. Elimination of paclitaxel appears to be biphasic
and near dose-proportional up to a dose of 300 mg/m2; aTherapeutics and Clinical Risk Management 2005:1(2) 110
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2.2-fold increase in dose (from 135 to 300 mg/m
2) is
associated with a 2.2-fold increase in peak concentration
and a 2.7-fold increase in AUC. At a dose of 375 mg/m2, the
clearance of paclitaxel decreased slightly, possibly
suggesting nonlinear disposition pathways. The clinical
relevance of this observation is unclear because few patients
were treated at doses above 300 mg/m
2 and the
recommended dose is well below those associated with
potential nonlinear pharmacokinetics. It is, however,
significant that ABI-007 displays linear pharmacokinetics
over the clinically relevant dose range of 135–300 mg/m2;
over a similar dose
 range, Taxol AUC∞ is nonlinear (Gianni
et al 1995; Kearns 1997; Mross et al 2000).
The pharmacokinetics of paclitaxel administered as ABI-
007 or Taxol were recently compared (Hawkins et al 2004).
Pharmacokinetic parameters are summarized in Table 3.
Patients with advanced solid tumors were randomized to
receive either ABI-007 260 mg/m
2 over 0.5 hour or Taxol
175 mg/m2 over 3 hours. As expected, owing to the
difference in the dose of paclitaxel administered and the
duration of infusion, statistically significant differences in
the maximum concentration and time to maximum
concentration were observed. Paclitaxel pharmacokinetic
parameters including AUC∞ and half-life were similar for
the two formulations: 14 789 ng · h/mL and 21.6 hours for
ABI-007 and 12 603 ng · h/mL and 20.5 hours for Taxol
(Table 3). Plasma clearance and volumes of distribution were
statistically different: 21.12 L/h · m2 and 663.8 L/m2 for ABI-
007 and 14.76 L/h · m2 and 433.4 L/m2 for Taxol (Hawkins
et al 2004). These in vivo pharmacokinetic findings are
consistent with the hypothesis that when paclitaxel is
administered as Taxol, it becomes sequestered in CrEL
micelles, prolonging circulation time in the intravascular
space (Sparreboom et al 1999), thereby decreasing systemic
clearance. The similarity of the terminal half-life of
paclitaxel obtained in patients receiving CrEL-containing
and CrEL-free formulations suggests that the principal effect
of CrEL on paclitaxel clearance is related to changes in drug
distribution rather than drug elimination.
Paclitaxel metabolism and
elimination
Paclitaxel is extensively metabolized in humans, and
systemic elimination of paclitaxel has been demonstrated
to be saturable in vivo (Huizing et al 1993; Sonnichsen et al
1994; Rowinsky 1997). Two cytochrome
 P450 (CYP)
isoenzymes are involved in the biotransformation of
paclitaxel by human liver microsomes (Cresteil et al 1994;
Harris et al 1994; Kumar et al 1994; Rahman et al 1994).
The formation
  of the major metabolite, 6α-
hydroxypaclitaxel, is catalyzed by CYP2C8 (Cresteil et al
1994; Rahman et al 1994), whereas the minor
 metabolite,
p-hydroxy-phenyl-C3´-paclitaxel, is formed by CYP3A4
(Cresteil et al 1994; Harris et al 1994; Kumar et al 1994). It
is believed that the dihydroxylated metabolite results from
stepwise hydroxylations at the two previously described sites
(Cresteil et al 1994).
Table 2 Summary of noncompartmental pharmacokinetic parameters for paclitaxel following administration of ABI-007; data are
presented as mean values (% coefficient of variation)
Infusion
Dose duration Number of Cmax AUC∞ ∞ ∞ ∞ ∞ Half-life CL Vz
(mg/m
2) (min) patients (ng/mL) (ng · h/mL) (h) (L/h · m
2) (L/m
2)
135 30 1 6100 6427 14.6 21.1 442
200 30 3 7757 (35) 9613 (20) 13.4 (67) 21.4 (21) 384 (64)
260 30 14 22969 (113) 14789 (45) 21.6(17.2) 21.1(43.8) 663.8(48.1)
300 30 5 13520 (7) 17610 (21) 14.6 (14) 17.7 (22) 370 (23)
375 30 4 19350 (15) 35805 (40) 13.2 (12) 11.9 (42) 236 (54)
Adapted from Hawkins et al (2004) and Ibrahim et al (2002).
Abbreviations: Cmax, peak concentration; AUC∞, area under the concentration-time curve from time 0 to infinity; CL, total body clearance; Vz, volume of distribution.
Table 3 Summary of pharmacokinetic parameters for
paclitaxel following administration of ABI-007 and Taxol; data
are presented as mean values (% coefficient of variation)
ABI-007 Taxol
Parameter 260 mg/m2 175 mg/m2 p-value
CL (L/h · m
2) 21.13 (43.8) 14.76 (31.8) 0.048
Vdss (L/m
2) 230.7 (54.3) 156.3 (43.2) 0.211
Vz (L/m2) 663.8 (48.1) 433.4 (31.1) 0.040
AUC∞ (ng · h/mL) 14 788.6 (45.3) 12 602.7 (21.0) 0.524
Cmax (ng/mL) 22 968.6 (112.5) 3543.3 (57.2) < 0.001
tmax (h) 0.36 (45.2) 20.14 (55.8) < 0.001
t½ (h) 21.6 (17.2) 20.5 (14.6) 0.479
Data adapted from Hawkins et al (2004).
Abbreviations: CL, total body clearance; Vdss, volume of distribution at steady
state; Vz, volume of distribution; AUC∞, area under the concentration-time curve
from time 0 to infinity; Cmax, peak concentration; tmax, time to peak
concentration; t½, half-life.Therapeutics and Clinical Risk Management 2005:1(2) 111
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The hepatobiliary elimination of paclitaxel in a CrEL-
containing formulation has been investigated using an
isolated perfused rat-liver model. In this study, CrEL caused
a statistically significant dose-dependent inhibition of the
elimination of paclitaxel. After a dose of CrEL, a 9-fold
increase in AUC, 9-fold decrease in total clearance, and 5-
fold increase in elimination half-life of paclitaxel were
observed. Thereby, this study demonstrated the major effect
of CrEL was to inhibit the hepatic elimination of paclitaxel
in the isolated perfused rat liver, primarily by preventing
the drug from reaching sites of metabolism and excretion
(Ellis and Webster 1999). These results are consistent with
other in vitro studies reporting a possible effect of CrEL on
drug distribution, including decreased uptake of paclitaxel
into human liver slices (Sonnichsen and Relling 1994) and
by human tumor cell lines (Liebmann et al 1994).
There is also some evidence in this study that CrEL
inhibited paclitaxel metabolism. In both humans and rodents,
paclitaxel is eliminated primarily by microsomal
hydroxylation followed by biliary excretion, with 3´-p-
hydroxypaclitaxel being a major rat metabolite (Monsarrat
et al 1990) and 6α-hydroxypaclitaxel being the major human
metabolite (Monsarrat et al 1993). In this study the major
metabolite in bile co-eluted with 3´-p-hydroxypaclitaxel, and
when normalized to biliary paclitaxel concentrations the
biliary excretion was decreased by CrEL. A concomitant
increase in these metabolites in either perfusate or liver was
not observed, suggesting that formation of these metabolites
rather than excretion was inhibited.
There is little information on the effect of CrEL on
microsomal metabolism. It has been reported that at
clinically achievable concentrations CrEL prevented the
metabolism of paclitaxel to 6α-hydroxypaclitaxel in human
liver microsomes (Jamis-Dow et al 1995). Cremophor
RH40, a similar polyoxyl hydrogenated castor oil, was
shown to inhibit CYP3A4-mediated nifedipine oxidation
in hepatic microsomes (Wandel et al 2003). No information
is currently available on the in vitro or in vivo metabolism
of paclitaxel formulated as ABI-007, nor is it known how
the pharmacokinetic profile of coadministered agents which
are substrates for the CYP system will be affected.
Paclitaxel pharmacodynamics
Pharmacokinetic–pharmacodynamic relationships have
been proposed for paclitaxel disposition and two of its major
toxicities, myelosuppression (predominantly neutropenia)
and neurotoxicity. The incidence of neutropenia associated
with paclitaxel has been evaluated as a function of total dose,
AUC, and peak plasma concentration (ten Bokkel Huinink
et al 1993), and correlation was found between these
pharmacokinetic parameters and neutropenia. The
observation that a 24-hour infusion schedule, at a dose of
135 or 175 mg/m2, is associated with a much greater degree
of neutropenia is compatible with a hypothesis that
neutropenia is likely to be related to the duration that the
plasma paclitaxel concentrations remain at or above a
“threshold” concentration (Huizing et al 1993). Gianni et al
(1995) have suggested that the relationship between the
length of time that plasma paclitaxel concentrations
exceeded 0.05 µmol/L and the resulting degree of
neutropenia can be well described by a sigmoid-Emax
model, in which the length of time that paclitaxel
concentrations remain above a given value is a function of
dose, schedule, and individual patient pharmacokinetic
parameters.
Neuropathy and musculoskeletal toxicities also have
been related to paclitaxel pharmacokinetic parameters.
Neurotoxicity in adults has been associated both with
repetitive paclitaxel doses and with paclitaxel doses that
exceed 250 mg/m
2 (Rowinsky et al 1992). Additional risk
factors for neurologic toxicities include prior neuropathy
and prior neurotoxic chemotherapy (Donehower and
Rowinsky 1993).
Paclitaxel–anticancer drug
interactions
Clinically significant drug interactions with paclitaxel have
been reported. Pharmacodynamic interactions with
paclitaxel can be sequence or schedule dependent. Because
paclitaxel undergoes hepatic oxidation via the CYP system,
pharmacokinetic interactions due to enzyme induction or
inhibition can also occur. Clinically significant interactions
with paclitaxel have been reported for carboplatin, cisplatin,
doxorubicin, epirubicin, and anticonvulsants. Administration
of paclitaxel prior to doxorubicin and epirubicin results in
an increase in the AUC of doxorubicin and epirubicin and
enhanced toxicity (Holmes et al 1996; Esposito et al 1999;
Venturini et al 2000). Conversely, paclitaxel administration
following cisplatin results in an increase in myelo-
suppression, possibly due to deceased paclitaxel clearance
(Rowinsky et al 1991). With concurrent anticonvulsant
therapy, CYP enzyme induction results in decreased
paclitaxel plasma steady-state concentrations (Chang et al
1998). Other drug interactions with paclitaxel have been
reported in preliminary studies, but the clinical significance
has not been established (Baker and Dorr 2001).Therapeutics and Clinical Risk Management 2005:1(2) 112
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An advantageous sequence-dependent pharmaco-
dynamic interaction has been observed when paclitaxel is
infused prior to carboplatin, resulting in decreased platelet
toxicity with no effect on pharmacokinetics (Bookman et al
1996; Baker 1997; Huizing et al 1997; van Warmerdam et
al 1997; Belani et al 1999; Baker and Dorr 2001). Despite
no change in the pharmacokinetics of either compound,
examination of the relationship between carboplatin
systemic exposure and thrombocytopenia revealed that the
carboplatin AUC associated with a 50% decrease in platelet
count increased from 34 µg · h/mL when carboplatin was
given alone to 57 µg · h/mL when it was administered after
paclitaxel (Baker 1997; Belani et al 1999). The mechanism
of this interaction is not clearly understood.
Clinical experience with ABI-007
In the first phase I clinical trial in patients with advanced or
refractory cancer, 19 patients received doses of ABI-007
ranging from 135 to 375 mg/m2 given as a 30-minute
intravenous infusion every 3 weeks, without any
premedication (Ibrahim et al 2002). As expected, no
hypersensitivity reactions were observed during the infusion
period, and hematological toxicity was mild and not
cumulative. The dose-limiting toxicity, which occurred in
three of six patients treated at 375 mg/m2, consisted of
sensory neuropathy, stomatitis, and superficial keratopathy.
The maximum tolerated dose at that administration schedule
was determined to be 300 mg/m2.
The maximum tolerated dose of ABI-007 given on a
weekly basis has also been determined. In a phase I
study, 39 patients with advanced non-hematologic
malignancies received doses of ABI-007 ranging from 80
to 200 mg/m2/day as a 30-minute infusion once a week for
3 weeks followed by a week of rest (Nyman et al 2004).
Patients were divided into two groups, those who had been
heavily pretreated with prior chemotherapy and those who
had not. The maximum tolerated dose of ABI-007 was
100 mg/m
2/week in patients who had previously been
heavily pretreated, with the dose-limiting toxicity of grade
4 neutropenia. In the group of patients who had not been
heavily pretreated, grade 3 peripheral neuropathy was the
dose-limiting toxicity at 150 mg/m
2/week. Five patients, all
of whom had prior therapy with paclitaxel, demonstrated a
partial response. This study provides evidence that ABI-
007 can be given safely on a weekly schedule.
Two phase II trials of ABI-007, using an every-3-week
administration regimen have been conducted in patients with
metastatic breast cancer. In the first trial, 43 patients were
treated with ABI-007 at a dose of 175 mg/m2 (Ibrahim et al
2002). The adverse event profile was similar to that
described for the phase I daily dosing study, with mild
hematological toxicity, no allergic reactions, and no grade
3 or 4 non-hematological toxicity other than vomiting in
2% of patients. Three patients had complete responses and
18 achieved partial responses for an overall objective
response rate of 51% (Ibrahim et al 2002). In the second
trial, 63 patients were treated at a dose of 300 mg/mL.
Neutropenia was noted, as well as peripheral neuropathy
grades 3/4 in 10% of patients, myalgia in 5%, vomiting in
2%, diarrhea in 3%, rash in 2%, and amblyopia in 2%, but
none developed hypersensitivity reactions. Three patients
had complete responses, and 34 achieved partial responses,
for an overall objective response rate of 61%.
ABI-007 was compared against the standard paclitaxel
formulation Taxol in a phase III trial in patients with
metastatic breast cancer (O’Shaughnessy et al 2003). This
study randomized 454 patients to either ABI-007
260 mg/m
2 infused over 30 minutes once every 3 weeks
without premedication or Taxol 175 mg/m2 administered
over 3 hours once every 3 weeks with premedication,
including dexamethasone and antihistamines. Patients were
randomized in a 1:1 fashion and were required to have
measurable disease. Patients previously treated with a taxane
were excluded; however, 78% of patients had been exposed
to prior anthracyclines. Approximately 40% of patients
received treatment on trial as first-line therapy, 40% as
second-line therapy, and approximately 20% as third-line
therapy or greater.
In this phase III study, patients treated with ABI-007
achieved a significantly higher objective response rate and
time to progression than those treated with Taxol. Based on
an investigator-scored assessment, the overall response rate
for ABI-007 was 33% compared with 19% for Taxol
(p = 0.001) with a median time to progression of 21.9 weeks
for ABI-007 versus 16.1 weeks for Taxol (p = 0.03). A
blinded independent radiology review was conducted and
the objective response rate for all patients treated with Taxol
was 10% vs 21% among patients treated with ABI-007
(p = 0.002). While overall response rate was lower in both
the ABI-007 and paclitaxel arms according to the blinded
independent radiology review as compared with an
investigator-scored assessment, treatment with ABI-007
resulted in a significantly superior response compared with
paclitaxel formulated in CrEL.
Consistent with the early phase studies, there was no
incidence of grade 3/4 hypersensitivity reactions in the groupTherapeutics and Clinical Risk Management 2005:1(2) 113
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of patients treated with ABI-007, despite the absence of
premedication. Grade 4 neutropenia was significantly
reduced in patients treated with ABI-007 occurring in only
9% of patients compared with 22% treated with Taxol
(p = 0.001). Grade 3 sensory neuropathy was higher in the
ABI-007 arm (10%) than in the Taxol arm (2%), with no
episodes of grade 4 neuropathy. However, sensory
neuropathy was improved to grades 1 or 2 within a median
of 22 days if ABI-007 was withheld. Flushing occurred more
frequently in patients treated with Taxol (5%) than in those
treated with ABI-007 (less than 1%).
Conclusion and future
investigations
Paclitaxel is an anticancer agent that has been shown to be
effective in the treatment of a variety of solid tumors;
however, owing to its insolubility paclitaxel is formulated
with the micelle-forming vehicle CrEL, which results in
increased toxicity and altered pharmacokinetics of
paclitaxel. ABI-007 is a CrEL-free, albumin-stabilized,
nanoparticle paclitaxel formulation that has been shown to
be free from infusion-related hypersensitivity reactions,
which allows higher paclitaxel doses to be administered over
a shorter infusion duration. Pharmacokinetic studies indicate
that in contrast to CrEL-containing paclitaxel, ABI-007
displays linear pharmacokinetics over the clinically relevant
dose range of 135–300 mg/m
2. In a phase III study
conducted in patients with metastatic breast cancer, patients
treated with ABI-007 achieved a significantly higher
objective response rate and time to progression than those
treated with CrEL-containing paclitaxel.
When paclitaxel is given concurrently with other drugs,
pharmacokinetic and pharmacodynamic interactions may
occur. Because paclitaxel is extensively metabolized by
hepatic CYP3A4 and CYP2C8, drugs that are metabolized
by, inhibit, or induce these enzymes have the potential to
alter paclitaxel clearance. The pharmacodynamics of drugs
given in combination with paclitaxel can also be altered;
this may depend on the sequence or schedule of
administration and can yield both favorable and undesirable
results. Many of the pharmacokinetic and pharmacodynamic
interactions with paclitaxel have been described in studies
employing CrEL-containing paclitaxel. Therefore, the effect
of paclitaxel administered as ABI-007 needs to be assessed.
Clinical data suggest that use of this nanoparticle
albumin-bound paclitaxel formulation may enable clinicians
to administer paclitaxel at higher doses with less toxicity
than is seen with CrEL-containing paclitaxel. It is essential
to relate the pharmacokinetics of paclitaxel to both the toxic
and therapeutic outcomes resulting from its use so that
optimal dosing strategies can be utilized. As the development
of ABI-007 moves forward it will be important to assess
the effect of this delivery vehicle on the pharmacokinetics
of paclitaxel when it is administered in combination with
other drugs. Clinical trials investigating the role of ABI-
007 in combination with other antineoplastic agents are
warranted.
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